Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002014493 | SCV002229918 | pathogenic | Bardet-Biedl syndrome | 2022-07-01 | criteria provided, single submitter | clinical testing | This sequence change is a complex rearrangement involving exon(s) 1-7 of the BBS1 gene. It does not change the copy number of any exons. Although the exact nature of the event is unknown, it is likely that this is a large inversion event including exon(s) 1-7, that would either disrupt the transcription or result in a truncated protein product. Loss-of-function variants in BBS1 are known to be pathogenic (PMID: 12118255, 21520335, 27032803). For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with BBS1-related conditions. |
Labcorp Genetics |
RCV002004587 | SCV002231000 | pathogenic | Glycogen storage disease, type V | 2022-07-01 | criteria provided, single submitter | clinical testing | For these reasons, this variant has been classified as Pathogenic. This variant has not been reported in the literature in individuals affected with PYGM-related conditions. This sequence change is a complex rearrangement involving exon(s) 1-7 of the PYGM gene. It does not change the copy number of any exons. Although the exact nature of the event is unknown, it is likely that this is a large inversion event including exon(s) 1-7, that would either disrupt the transcription or result in a truncated protein product. Loss-of-function variants in PYGM are known to be pathogenic (PMID: 8316268, 16786513). |